Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections
Open Access
- 1 April 1983
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 23 (4), 565-570
- https://doi.org/10.1128/aac.23.4.565
Abstract
Moxalactam was used as initial, empirical therapy in 69 patients with a variety of serious bacterial infections, 32% of which were accompanied by bacteremia. Overall, the success rate was 83% and drug-related adverse effects were minimal. The drug was less efficacious in infections caused by aerobic gram-positive pathogens than it was in those caused by gram-negative pathogens. The following gram-positive organisms were associated with special problems during moxalactam therapy: Streptococcus pneumoniae (development of meningitis and a relapse of pneumonia with a more resistant strain), Staphylococcus epidermidis (in vivo emergence of moxalactam resistance, and the enterococci (failure of therapy and a fatal superinfection. Moxalactam performed well in infections caused by most gram-negative organisms, including aminoglycoside-resistant strains, but the previously reported emergence of gram-negative bacillary resistance to moxalactam during therapy was reconfirmed in our series with Serratia marcescens. The use of moxalactam in the treatment of gram-negative meningitis was further supported by a patient with meningitis-ventriculitis caused by Bacteroides fragilis who was cured with moxalactam after failure on chloramphenicol.This publication has 19 references indexed in Scilit:
- Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapyAntimicrobial Agents and Chemotherapy, 1981
- Comparative in vitro study in new cephalosporinsAntimicrobial Agents and Chemotherapy, 1981
- Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillinAntimicrobial Agents and Chemotherapy, 1981
- Clinical evaluation of moxalactamAntimicrobial Agents and Chemotherapy, 1981
- Therapy of lower respiratory tract infections with moxalactamAntimicrobial Agents and Chemotherapy, 1981
- Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1981
- In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1980
- Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycinAntimicrobial Agents and Chemotherapy, 1980
- Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new)Antimicrobial Agents and Chemotherapy, 1980
- In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibioticAntimicrobial Agents and Chemotherapy, 1980